We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Principal Deputy Commissioner Janet Woodcock announced Thursday that, after careful review, a new regulatory pathway for cannabidiol (CBD) review is needed and the agency is denying three citizen petitions to allow marketing of CBD products as dietary supplements. Read More
An FDA advisory committee yesterday recommended that the next generation of COVID-19 vaccines should combine the current primary vaccine against the original Wuhan strain and the bivalent booster against Omicron strains BA.4 and BA.5. Read More
The agency said it believes that the existing regulations balance “the need to incentivize the development of drugs for rare diseases and conditions with the need to provide patient access to orphan drugs.” Read More
Attorneys who work in the biopharmaceutical industry say the landmark $740 billion Inflation Reduction Act (IRA) — passed in August and beginning to go into effect this month to lower drug costs — is chaotic, hard to understand and has the drug industry very nervous. Read More
North American Custom Laboratories earned an FDA warning letter for failing to prove it had corrected manufacturing problems that could have impaired product sterility. Read More
The FDA’s Center for Drug Evaluation and Research (CDER) has concluded that its proposed quality management maturity (QMM) scoring system is “too complex,” based on findings from two pilot programs. Read More